Mark C. McKenna, Chairman, President & CEO: Prometheus Biosciences RXDX Sell · Filed 23/03/17

Trade details

Type: Insider sale
Amount: $2,903,500
Shares · price: 25,000 sh · $116.14 a share
Held after: 55,144 sh
Stock: Prometheus Biosciences RXDX
Person: Mark C. McKennaChairman, President & CEO
Trade date: 23/03/15
Filed: 23/03/17
Days to filing: 2 days

Sold 31.2% of holdings

Share of holding sold: 31.2%

Prometheus Biosciences trades, last 26 weeks

What else happened in Prometheus Biosciences around then

Filed or reported within 30 days of the trade day · 23/02/13~23/04/14

Mark C. McKenna's recent trades

Mark C. McKennaDirector
BuyApogee Therapeutics
Buy
Apogee Therapeutics
APGE
$623.1K
12,500 sh
$623.1K
Filed 24/12/16
Traded 24/12/12
Mark C. McKennaDirector
BuyApogee Therapeutics
Buy
Apogee Therapeutics
APGE
$367.7K
7,500 sh
$367.7K
Filed 24/12/16
Traded 24/12/12
Mark C. McKennaChairman, President & CEO
SellPrometheus Biosciences
Sell
Prometheus Biosciences
RXDX
$1.3M
10,620 sh
$1.3M
Filed 23/03/03
Traded 23/03/03
Mark C. McKennaChairman, President & CEO
SellPrometheus Biosciences
Sell
Prometheus Biosciences
RXDX
$87.7K
700 sh
$87.7K
Filed 23/03/03
Traded 23/03/01
Mark C. McKennaChairman, President & CEO
SellPrometheus Biosciences
Sell
Prometheus Biosciences
RXDX
$3M
25,000 sh
$3M
Filed 23/02/17
Traded 23/02/16